Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Twilio Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Twilio Inc trades at $268.1 (market cap $43.25B). The key difference: Twilio Inc is far larger — about 15.1× Dyne Therapeutics Inc. Common Stock's market cap, and Twilio Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Twilio Inc for 56 Days on average.
| DYN | TWLO | |
|---|---|---|
Market Cap | $2.86B | $43.25B |
Volume | 3,341,579 | 1,616,308 |
Sector | Health | Technology |
52-Week High | $26.78 | $301.27 |
52-Week Low | $14.60 | $106.23 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.18B | $41.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Twilio stock trades at $271.12, down 4.08% today, amid mixed signals. The technical outlook is bullish based on moving averages, with key support at $268. Fundamentally, revenue grew to $5.07B in 2025, with net income turning positive at $33.83M after years of losses. Recent news highlights its upcoming addition to the S&P 500 index effective October 6, 2026, a positive catalyst for institutional interest.
The outlook is cautiously optimistic given strong analyst support (76.9% buy ratings) and a consensus price target of $257.59, though the stock trades above this level. Risks include high valuation multiples (P/E 38.89) and competitive pressures in customer engagement software. Earnings beats in recent quarters support growth momentum, but investors should weigh rich valuations against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
